There is a lack of data on the use of short-term androgen deprivation therapy (stADT) in combination with high-dose radiotherapy (RT) versus RT alone for patients with localized prostate cancer (PCa). The recent GETUG 14 randomized phase III trial has analyzed stADT plus RT to gain more insight on these treatments. Previous research has demonstrated the benefit of stADT for 4 months before and during RT for localized, intermediate-risk PCa. GETUG 14 recruited 376 patients with both intermediate- and high-risk PCa, randomizing them to receive either RT (n=191) or stADT plus RT (n=179). ...
Localized Prostate Cancer
Advertisement
Latest News
Dr. Greenstein shares insights on the overall survival benefit of apalutamide over enzalutamide in a recent real-world study.
Patients were guided through a VR experience to view their specific anatomy in a 3-dimensional space.
Data show that of patients with prostate cancer, Black men face higher incidence and mortality rates than White men.
For the treatment of localized prostate cancer, guidelines typically recommend the addition of ADT to RT in certain patients.
Drs. Stifelman and Ambinder discuss the novel approaches and adoption challenges of single-port and Da Vinci 5 systems.
Dr. Shore discusses treatment-related adverse events associated with apalutamide and ADT.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content based on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. Daneshmand talks about key studies and exciting developments in bladder cancer from the LUGPA 2024 Annual Meeting.
In part six of this roundtable series, the panelists finish their discussion by reviewing immunotherapy in prostate cancer.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
In part four of this roundtable series, the panelists discuss CRPC and the typical patterns of presentation.
Part three of this roundtable delves into genomic biomarkers and the use of doublet and triplet therapies for mHSPC.
Part two of the roundtable series explores ADT and novel hormonal therapies for patients with prostate cancer.
Advertisement
Advertisement
Trending
A recent study assessed pathologic and short-term oncological and survival outcomes of prostate cancer surgical approaches.
Dr. Daneshmand reviews data from ENVISION on mytomycin for patients with intermediate-risk bladder cancer.
Dr. Daneshmand talks about key studies and exciting developments in bladder cancer from the LUGPA 2024 Annual Meeting.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.